dc.contributor.author | Tabak, Fehmi | |
dc.contributor.author | Mete, Bilgul | |
dc.contributor.author | Ozaras, Resat | |
dc.contributor.author | Uraz, Suleyman | |
dc.contributor.author | Demirel, Aslihan | |
dc.date.accessioned | 2021-03-04T13:07:41Z | |
dc.date.available | 2021-03-04T13:07:41Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Ozaras R., Uraz S., Demirel A., Mete B., Tabak F., "Does resolved HBV or anti-HBc-only carry the same risk of HBV reactivation?", JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.24, sa.6, ss.477-478, 2018 | |
dc.identifier.issn | 1078-1552 | |
dc.identifier.other | av_7abdcda2-bc86-4f01-b710-e78b503e9162 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/84080 | |
dc.identifier.uri | https://doi.org/10.1177/1078155218782593 | |
dc.language.iso | eng | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | Eczacılık | |
dc.subject | Temel Eczacılık Bilimleri | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Temel Bilimler | |
dc.subject | ONKOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | FARMAKOLOJİ VE ECZACILIK | |
dc.subject | Farmakoloji ve Toksikoloji | |
dc.title | Does resolved HBV or anti-HBc-only carry the same risk of HBV reactivation? | |
dc.type | Makale | |
dc.relation.journal | JOURNAL OF ONCOLOGY PHARMACY PRACTICE | |
dc.contributor.department | İstanbul Bilim Üniversitesi , , | |
dc.identifier.volume | 24 | |
dc.identifier.issue | 6 | |
dc.identifier.startpage | 477 | |
dc.identifier.endpage | 478 | |
dc.contributor.firstauthorID | 256101 | |